Observation of the effect of intravenous injection of remidazolam / cyclophenol on Etomidate-Induced Myoclonus

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400089465

Enrollment

Unknown

Registered

2024-09-09

Start date

2023-03-13

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Etomidate-Induced Myoclonus

Interventions

R group:0.1mg/kg remidazolam (concentration 1mg/ml) +0.3mg/kg etomidate

CP1 group:0.2mg/kg cyclophenol (concentration 2mg/ml) +0.3mg/kg etomidate

CP2 group:0.1mg/kg cyclophenol (concentration 1mg/ml) +0.3mg/kg etomidate

C group:0.1ml/kg N.S.+0.3mg/kg etomidate

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 200 patients (50/group) undergoing selective general anesthesia induction ASA I-III Age>18 years BMI 18-28kg/m2

Exclusion criteria

Exclusion criteria: Patients with allergy to remidazolam, cyclophenol, and etomidate Patients with severe liver and kidney dysfunction Patients with neuromotor system diseases such as epilepsy, myasthenia gravis, Parkinson's disease, paraplegia/paraplegia

Design outcomes

Primary

Measure	Time frame
Degree of myoclonus;	—

Secondary

Measure	Time frame
BP;HR;SpO2;RR;Vt;EtCO2;BIS;myalgia after recovery;	—

Countries

China

Contacts

Public ContactLi Haoyi

Dalian Med Univ, Affiliated Hosp 2

lhy-yd@163.com+86 177 0987 1723

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026